Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Johann Poetzl
Observed names:
J. Poetzl,
Johann Pötzl,
Poetzl, Johann
Institution:
Hexal (Germany)
Observed institution:
Hexal (Germany)
ORCID:
0009-0006-7557-1555
Observed ORCID:
0009-0006-7557-1555
OpenAlex ID:
A5068353611
The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis
2017
·
C.E.M. Griffiths
, D. Thaçi
, et al.
·
British Journal of Dermatology
·
200
PDF
Multiple switches between GP 2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque‐type psoriasis: 30‐week results from the phase 3, confirmatory EGALITY study
2017
·
S. Gerdes
, D. Thaçi
, et al.
·
Journal of the European Academy of Dermatology and Venereology
·
84
PDF
2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation ( Part 3 –Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene & Cell Therapy and Vaccine Assays)
2021
·
Bart Corsaro
, Tong-yuan Yang
, et al.
·
Bioanalysis
·
67
PDF
Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study
2018
·
Marco Matucci-Cerinic
, Yannick Allanore
, et al.
·
RMD Open
·
45
PDF
2021 White Paper on Recent Issues in Bioanalysis: TAb/NAb, Viral Vector CDx, Shedding Assays; CRISPR/Cas9 & CAR-T Immunogenicity; PCR & Vaccine Assay Performance; ADA Assay Comparability & Cut Point Appropriateness ( Part 3 – Recommendations on Gene Therapy, Cell Therapy, Vaccine Assays; Immunogenicity of Biotherapeutics and Novel Modalities; Integrated Summary of Immunogenicity Harmonization)
2022
·
Lina Loo
, Shannon Harris
, et al.
·
Bioanalysis
·
41
PDF
GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods
2019
·
Oliver von Richter
, Lena Lemke
, et al.
·
Expert Opinion on Biological Therapy
·
35
GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes
2016
·
Oliver von Richter
, Andrej Skerjanec
, et al.
·
British Journal of Clinical Pharmacology
·
33
PDF
2021 White Paper on Recent Issues in Bioanalysis: ISR for Biomarkers, Liquid Biopsies, Spectral Cytometry, Inhalation/Oral & Multispecific Biotherapeutics, Accuracy/LLOQ for Flow Cytometry ( Part 2 – Recommendations on Biomarkers/CDx Assays Development & Validation, Cytometry Validation & Innovation, Biotherapeutics PK LBA Regulated Bioanalysis, Critical Reagents & Positive Controls Generation)
2022
·
Sarah Hersey
, Steve Keller
, et al.
·
Bioanalysis
·
30
PDF
Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study
2024
·
Sławomir Jeka
, Eva Dokoupilová
, et al.
·
Journal of Bone and Mineral Research
·
26
PDF
Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial
2020
·
Josef S Smolen
, Stanley B Cohen
, et al.
·
Rheumatology
·
26
2023 White Paper on Recent Issues in Bioanalysis: ISR for ADA Assays, the Rise of dPCR vs qPCR, International Reference Standards for Vaccine Assays, Anti-AAV TAb Post-Dose Assessment, NanoString Validation, ELISpot as Gold Standard (Part 3 – Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity & Technologies; Biotherapeutics Immunogenicity & Risk Assessment; ADA/NAb Assay/Reporting Harmonization)
2024
·
Johanna Mora
, Rachel Palmer
, et al.
·
Bioanalysis
·
24
PDF
2022 White Paper on Recent Issues in Bioanalysis: Fda Draft Guidance on Immunogenicity Information in Prescription Drug Labeling, Lnp & Viral Vectors Therapeutics/Vaccines Immunogenicity, Prolongation Effect, Ada Affinity, Risk-Based Approaches, Ngs, Qpcr, Ddpcr Assays ( Part 3 – Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity & Technologies; Immunogenicity & Risk Assessment of Biotherapeutics and Novel Modalities; NAb Assays Integrated Approach)
2023
·
Luying Pan
, Johanna Mora
, et al.
·
Bioanalysis
·
23
Signal-to-noise Ratio to Assess Magnitude, Kinetics and Impact on Pharmacokinetics of the Immune Response to an Adalimumab Biosimilar
2023
·
Davide Guerrieri
, Matej Horvat
, et al.
·
Bioanalysis
·
18
2024 White Paper on Recent Issues in Bioanalysis: Evolution of Immunogenicity Assessment beyond ADA/NAb; Regulated Genomic/NGS Assays; Hypersensitivity Reactions; Minimum Noise Reduction; False Positive Range; Modernized Vaccine Approaches; NAb/TAb Correlation (PART 3A – Recommendations on Advanced Strategies for Molecular Assays and Immunogenicity of Gene Therapy, Cell Therapy, Vaccine; Biotherapeutics Immunogenicity Assessment & Clinical Relevance PART 3B – Regulatory Agencies’ Input on Immunogenicity/Technologies of Biotherapeutics, Gene, Cell & Vaccine Therapies)
2025
·
Omar Tounekti
, Sandra Prior
, et al.
·
Bioanalysis
·
17
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab
2024
·
Krzysztof Selmaj
, Karsten Roth
, et al.
·
BioDrugs
·
16
PDF
Comparative immunogenicity assessment of biosimilar natalizumab to its reference medicine: a matching immunogenicity profile
2024
·
Paul Chamberlain
, Bernhard Hemmer
, et al.
·
Frontiers in Immunology
·
12
PDF
The Totality of Evidence for SDZ-deno: A Biosimilar to Reference Denosumab
2024
·
Barbara Vogg
, Johann Poetzl
, et al.
·
Clinical Therapeutics
·
8
PDF
Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males
2024
·
Barbara Vogg
, Johann Poetzl
, et al.
·
Expert Opinion on Biological Therapy
·
8
PDF
THU0145 Pharmacokinetics and Safety of GP2015, A Proposed Etanercept Biosimilar, and Etanercept Originator Product in Healthy Male Subjects: A Randomised Two-Way Crossover Study
2016
·
M. Afonso
, S. Sanguino Heinrich
, et al.
·
Annals of the Rheumatic Diseases
·
8
2025 White Paper on Recent Issues in Bioanalysis: Redosing Patients with AAV Gene Therapy; CRS Immunogenicity Risk; Shedding Assays; NHP Studies Immunogenicity; CMC vs Bioanalytical Assays; Artificial Intelligence-Powered Genomic Pipelines for NGS ( PART 3A – Recommendations on Gene, Cell, and Vaccine Therapies Immunogenicity & Technologies; Biotherapeutics & Biosimilars Immunogenicity Assessment & Clinical Relevance PART 3B – Regulatory Agencies’ Input on Immunogenicity/Technologies of Biotherapeutics, Gene, Cell & Vaccine Therapies)
2025
·
Omar Tounekti
, Sophie Shubow
, et al.
·
Bioanalysis
·
6
PDF
State‐of‐the‐art immunogenicity evaluation in phase 3 confirmatory study ( EGALITY ) with etanercept biosimilar GP 2015
2017
·
J. Poetzl
, I. Arlt
, et al.
·
Journal of the European Academy of Dermatology and Venereology
·
5
Comparing anti-drug antibody signal-to-noise ratios to assess immunogenicity and interchangeability in adalimumab biosimilar studies
2024
·
Lena Lemke
, Andrew Blauvelt
, et al.
·
Expert Opinion on Biological Therapy
·
4
PDF
Simultaneous isotyping and semi-quantitation of anti-drug antibodies to an IgG1 biotherapeutic using hybrid LBA-LC-MS/MS
2024
·
Frank B. Schalk
, Davide Guerrieri
, et al.
·
Bioanalysis
·
3
PDF
AB0412 Preclinical PK and Safety Assessment of the Proposed Adalimumab Biosimilar Gp2017, Compared to Humira®
2014
·
U. Kronthaler
, M. Baron
, et al.
·
Annals of the Rheumatic Diseases
·
2
From analytical similarity to clinical confidence: how regulatory evolution ensures comparable immunogenicity in streamlined biosimilar development
2026
·
Sandra Ribes
, Marc Rosenbaum
, et al.
·
Bioanalysis
·
1
Show more works
View as search
Works count:
35
Citation count:
743
H-index:
15
I10-index:
16
Year
Topic
Type